Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis
Author:
Funder
Cancer Research UK
Publisher
Elsevier BV
Subject
Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Reference35 articles.
1. Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis;Berry;Ann Oncol,2015
2. The impact of complete chemotherapy stop on the overall survival of patients with advanced colorectal cancer in first-line setting: A meta-analysis of randomized trials;Pereira;Acta Oncol,2015
3. Intermittent versus continuous chemotherapy for first-line treatment of unresectable metastatic colorectal cancer (CCRm): systematic review and meta-analysis;Botrel;Value in Health,2011
4. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group;Simkens;Lancet,2015
5. Maintenance strategies after fi rst-line oxaliplatin plus fl uoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial;Hegewisch-Becker;Lancet Oncol,2015
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy of different maintenance strategies for RAS wild-type colorectal cancer: A network meta-analysis;Digestive and Liver Disease;2024-02
2. Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT;Efficacy and Mechanism Evaluation;2022-12
3. Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer;British Journal of Cancer;2022-10-13
4. Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer;Journal of Cancer Policy;2022-09
5. Reply to A. Kurreck et al and M.S. Copur et al;Journal of Clinical Oncology;2022-04-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3